OptiNose (OPTN) Stock Forecast, Price Target & Predictions
OPTN Stock Forecast
OptiNose stock forecast is as follows: an average price target of $4.00 (represents a 320.30% upside from OPTN’s last price of $0.95) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OPTN Price Target
The average price target for OptiNose (OPTN) is $4.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $3.00. This represents a potential 320.30% upside from OPTN's last price of $0.95.
OPTN Analyst Ratings
According to 5 Wall Street analysts, OptiNose's rating consensus is 'Buy'. The analyst rating breakdown for OPTN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
OptiNose Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Thomas Flaten | Loop Capital Markets | $3.00 | $1.12 | 167.86% | 215.23% |
| Nov 14, 2022 | - | BMO Capital | $5.00 | $2.01 | 148.76% | 425.38% |
| Jun 13, 2022 | David Amsellem | Piper Sandler | $4.00 | $2.62 | 52.56% | 320.30% |
The latest OptiNose stock forecast, released on May 15, 2024 by Thomas Flaten from Loop Capital Markets, set a price target of $3.00, which represents a 167.86% increase from the stock price at the time of the forecast ($1.12), and a 215.23% increase from OPTN last price ($0.95).
OptiNose Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $0.95 | $0.95 | $0.95 |
| Upside/Downside | -100.00% | -100.00% | 215.23% |
In the current month, the average price target of OptiNose stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OptiNose's last price of $0.95. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 15, 2024 | Lake Street | Buy | Buy | Hold |
| Aug 21, 2023 | Lake Street | - | Buy | Initialise |
| Aug 21, 2023 | Noble Capital Markets | - | Outperform | Initialise |
| Aug 21, 2023 | Cowen & Co. | - | Outperform | Initialise |
| Nov 14, 2022 | BMO Capital | Outperform | Outperform | Hold |
| Jun 13, 2022 | Piper Sandler | Overweight | Overweight | Hold |
OptiNose's last stock rating was published by Lake Street on May 15, 2024. The company gave OPTN a "Buy" rating, the same as its previous rate.
OptiNose Financial Forecast
OptiNose Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $19.86M | $19.82M | $19.45M | $11.85M | $20.86M | $20.08M | $20.58M | $14.76M | $22.51M | $21.83M | $18.36M | $11.96M | $16.35M | $15.44M | $10.27M | $7.06M | $11.08M | $12.40M | $6.68M | $4.48M | $865.00K |
| Avg Forecast | $39.50M | $33.30M | $28.80M | $21.20M | $28.21M | $23.00M | $20.58M | $14.90M | $19.26M | $18.68M | $17.36M | $9.85M | $20.71M | $23.35M | $20.55M | $16.71M | $21.75M | $23.50M | $18.08M | $11.17M | $17.92M | $14.58M | $9.79M | $7.72M | $11.64M | $8.58M | $6.62M | $3.80M | $779.57K |
| High Forecast | $42.23M | $35.60M | $30.79M | $22.67M | $30.16M | $24.76M | $22.00M | $15.93M | $20.60M | $19.97M | $18.56M | $10.53M | $22.14M | $24.96M | $22.05M | $17.93M | $23.33M | $25.22M | $19.40M | $11.98M | $19.22M | $15.64M | $10.51M | $8.28M | $12.49M | $9.21M | $7.10M | $4.08M | $935.48K |
| Low Forecast | $34.69M | $29.25M | $25.29M | $18.62M | $24.78M | $20.34M | $18.08M | $13.09M | $16.92M | $16.41M | $15.25M | $8.65M | $18.19M | $20.51M | $18.11M | $14.73M | $19.17M | $20.71M | $15.94M | $9.84M | $15.79M | $12.85M | $8.63M | $6.80M | $10.26M | $7.56M | $5.83M | $3.35M | $623.65K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 1.06% | 1.12% | 1.20% | 1.01% | 0.86% | 1.00% | 0.88% | 1.03% | 0.93% | 1.02% | 1.07% | 0.91% | 1.06% | 1.05% | 0.91% | 0.95% | 1.44% | 1.01% | 1.18% | 1.11% |
OptiNose's average Quarter revenue forecast for Mar 24 based on 1 analysts is $14.90M, with a low forecast of $13.09M, and a high forecast of $15.93M. OPTN's average Quarter revenue forecast represents a -24.99% decrease compared to the company's last Quarter revenue of $19.86M (Dec 23).
OptiNose EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $-4.95M | $-1.69M | $-4.17M | $-14.37M | $-8.36M | $-10.61M | $-15.17M | $-21.14M | $-11.44M | $-12.57M | $-19.33M | $-22.01M | $-19.94M | $-17.39M | $-22.30M | $-25.68M | $-22.29M | $-26.15M | $-24.66M | $-26.22M | $-28.22M |
| Avg Forecast | $-31.11M | $-26.23M | $-22.68M | $-16.70M | $-22.22M | $-18.12M | $-16.21M | $-11.73M | $-15.17M | $-14.71M | $-13.67M | $-7.76M | $-16.31M | $-15.36M | $-16.18M | $-18.01M | $-17.13M | $-18.51M | $-14.24M | $-23.67M | $-14.11M | $-11.48M | $-7.71M | $-26.47M | $-9.17M | $-6.76M | $-5.21M | $-26.59M | $-25.13M |
| High Forecast | $-27.32M | $-23.03M | $-19.92M | $-14.66M | $-19.51M | $-16.02M | $-14.24M | $-10.31M | $-13.32M | $-12.92M | $-12.01M | $-6.81M | $-14.33M | $-12.29M | $-14.26M | $-14.41M | $-15.10M | $-16.31M | $-12.55M | $-18.94M | $-12.44M | $-10.12M | $-6.80M | $-21.18M | $-8.08M | $-5.96M | $-4.59M | $-21.27M | $-20.10M |
| Low Forecast | $-33.26M | $-28.04M | $-24.25M | $-17.85M | $-23.76M | $-19.50M | $-17.33M | $-12.55M | $-16.22M | $-15.73M | $-14.62M | $-8.29M | $-17.44M | $-18.43M | $-17.36M | $-21.61M | $-18.38M | $-19.86M | $-15.28M | $-28.41M | $-15.14M | $-12.32M | $-8.27M | $-31.77M | $-9.83M | $-7.25M | $-5.59M | $-31.90M | $-30.16M |
| Surprise % | - | - | - | - | - | - | - | - | 0.33% | 0.12% | 0.31% | 1.85% | 0.51% | 0.69% | 0.94% | 1.17% | 0.67% | 0.68% | 1.36% | 0.93% | 1.41% | 1.51% | 2.89% | 0.97% | 2.43% | 3.87% | 4.73% | 0.99% | 1.12% |
undefined analysts predict OPTN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than OptiNose's previous annual EBITDA (undefined) of $NaN.
OptiNose Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $-10.16M | $-9.29M | $2.63M | $-18.65M | $-17.33M | $-14.95M | $-19.40M | $-25.33M | $-19.64M | $-17.12M | $-23.50M | $-26.05M | $-23.86M | $-21.21M | $-25.85M | $-28.86M | $-25.00M | $-28.81M | $-27.38M | $-28.87M | $-30.57M |
| Avg Forecast | $1.51M | $-1.51M | $-3.01M | $-7.53M | $-4.14M | $-7.91M | $-11.66M | $-16.01M | $-12.39M | $-14.22M | $-16.36M | $-21.10M | $-26.34M | $-20.92M | $-36.54M | $-21.58M | $-39.18M | $-53.95M | $-62.79M | $-28.02M | $-69.57M | $-78.86M | $-84.39M | $-29.74M | $-93.43M | $-106.39M | $-110.91M | $-29.28M | $-27.22M |
| High Forecast | $1.64M | $-1.27M | $-2.54M | $-6.34M | $-3.49M | $-6.33M | $-9.81M | $-13.48M | $-11.97M | $-11.97M | $-13.77M | $-17.76M | $-22.17M | $-16.74M | $-30.91M | $-17.26M | $-33.14M | $-45.63M | $-53.10M | $-22.42M | $-58.84M | $-66.70M | $-71.37M | $-23.80M | $-79.02M | $-89.98M | $-93.80M | $-23.42M | $-21.78M |
| Low Forecast | $1.27M | $-1.64M | $-3.28M | $-8.21M | $-4.52M | $-9.49M | $-12.70M | $-17.45M | $-12.80M | $-15.50M | $-17.82M | $-22.99M | $-28.71M | $-25.10M | $-40.01M | $-25.90M | $-42.89M | $-59.06M | $-68.74M | $-33.62M | $-76.16M | $-86.34M | $-92.38M | $-35.69M | $-102.28M | $-116.47M | $-121.42M | $-35.14M | $-32.67M |
| Surprise % | - | - | - | - | - | - | - | - | 0.82% | 0.65% | -0.16% | 0.88% | 0.66% | 0.71% | 0.53% | 1.17% | 0.50% | 0.32% | 0.37% | 0.93% | 0.34% | 0.27% | 0.31% | 0.97% | 0.27% | 0.27% | 0.25% | 0.99% | 1.12% |
OptiNose's average Quarter net income forecast for Sep 23 is $-14.22M, with a range of $-15.50M to $-11.97M. OPTN's average Quarter net income forecast represents a -641.46% decrease compared to the company's last Quarter net income of $2.63M (Jun 23).
OptiNose SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $18.96M | $18.01M | $20.10M | $22.72M | $23.31M | $25.49M | $29.51M | $29.34M | $26.34M | $25.80M | $27.31M | $27.18M | $28.11M | $24.57M | $25.70M | $27.06M | $26.55M | $25.27M | $26.00M | $26.34M | $27.82M |
| Avg Forecast | $71.99M | $60.69M | $52.49M | $38.64M | $51.42M | $41.92M | $37.51M | $27.16M | $35.11M | $34.04M | $31.64M | $17.95M | $37.75M | $42.56M | $37.45M | $30.45M | $39.64M | $42.83M | $32.95M | $20.35M | $32.66M | $26.57M | $17.85M | $14.07M | $21.21M | $15.64M | $12.06M | $6.93M | $1.42M |
| High Forecast | $76.96M | $64.88M | $56.12M | $41.31M | $54.97M | $45.13M | $40.10M | $29.03M | $37.53M | $36.40M | $33.83M | $19.19M | $40.36M | $45.50M | $40.18M | $32.67M | $42.53M | $45.96M | $35.35M | $21.83M | $35.03M | $28.51M | $19.15M | $15.09M | $22.76M | $16.78M | $12.94M | $7.43M | $1.70M |
| Low Forecast | $63.22M | $53.30M | $46.10M | $33.93M | $45.16M | $37.08M | $32.94M | $23.85M | $30.83M | $29.90M | $27.79M | $15.77M | $33.15M | $37.37M | $33.01M | $26.84M | $34.94M | $37.75M | $29.04M | $17.94M | $28.78M | $23.42M | $15.73M | $12.40M | $18.70M | $13.78M | $10.63M | $6.10M | $1.14M |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.53% | 0.64% | 1.27% | 0.62% | 0.60% | 0.79% | 0.96% | 0.66% | 0.60% | 0.83% | 1.34% | 0.86% | 0.92% | 1.44% | 1.92% | 1.25% | 1.62% | 2.16% | 3.80% | 19.58% |
OptiNose's average Quarter SG&A projection for Mar 24 is $27.16M, based on 1 Wall Street analysts, with a range of $23.85M to $29.03M. The forecast indicates a 43.22% rise compared to OPTN last annual SG&A of $18.96M (Dec 23).
OptiNose EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.08 | - | $-0.17 | $-0.18 | $-0.18 | $-0.23 | $-0.31 | $-0.29 | $-0.32 | $-0.44 | $-0.49 | $-0.46 | $-0.43 | $-0.56 | $-0.63 | $-0.58 | $-0.69 | $-0.66 | $-0.70 | $-0.81 |
| Avg Forecast | $0.01 | $-0.01 | $-0.02 | $-0.05 | $-0.03 | $-0.05 | $-0.08 | $-0.11 | $-0.08 | $-0.09 | $-0.11 | $-0.14 | $-0.17 | $-0.19 | $-0.24 | $-0.27 | $-0.26 | $-0.36 | $-0.42 | $-0.53 | $-0.46 | $-0.52 | $-0.56 | $-0.66 | $-0.62 | $-0.71 | $-0.74 | $-0.71 | $-0.65 |
| High Forecast | $0.01 | $-0.01 | $-0.02 | $-0.04 | $-0.02 | $-0.04 | $-0.07 | $-0.09 | $-0.08 | $-0.08 | $-0.09 | $-0.12 | $-0.15 | $-0.16 | $-0.21 | $-0.23 | $-0.22 | $-0.30 | $-0.35 | $-0.45 | $-0.39 | $-0.44 | $-0.47 | $-0.55 | $-0.52 | $-0.60 | $-0.62 | $-0.60 | $-0.52 |
| Low Forecast | $0.01 | $-0.01 | $-0.02 | $-0.05 | $-0.03 | $-0.06 | $-0.08 | $-0.12 | $-0.08 | $-0.10 | $-0.12 | $-0.15 | $-0.19 | $-0.20 | $-0.27 | $-0.30 | $-0.28 | $-0.39 | $-0.46 | $-0.58 | $-0.51 | $-0.57 | $-0.61 | $-0.72 | $-0.68 | $-0.77 | $-0.81 | $-0.78 | $-0.78 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.88% | - | 1.21% | 1.03% | 0.97% | 0.95% | 1.15% | 1.12% | 0.89% | 1.06% | 0.92% | 1.00% | 0.82% | 1.00% | 0.96% | 0.94% | 0.98% | 0.90% | 0.98% | 1.25% |
According to undefined Wall Street analysts, OptiNose's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OPTN previous annual EPS of $NaN (undefined).
OptiNose Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.94 | $10.00 | 415.46% | - |
| OPTN | OptiNose | $0.95 | $4.00 | 321.05% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.51 | $15.00 | 232.59% | Buy |
| DVAX | Dynavax | $11.03 | $24.50 | 122.12% | Buy |
| LFCR | Lifecore Biomedical | $4.77 | $8.00 | 67.71% | Buy |
| AMPH | Amphastar Pharmaceuticals | $45.38 | $66.00 | 45.44% | Buy |
| ALKS | Alkermes | $26.86 | $35.50 | 32.17% | Buy |
| ITCI | Intra-Cellular Therapies | $73.54 | $94.00 | 27.82% | Buy |
| NBIX | Neurocrine Biosciences | $120.17 | $144.42 | 20.18% | Buy |
| ANIP | ANI Pharmaceuticals | $60.51 | $71.00 | 17.34% | Buy |
| COLL | Collegium Pharmaceutical | $37.19 | $41.50 | 11.59% | Buy |
| PBH | Prestige Consumer Healthcare | $74.34 | $82.00 | 10.30% | Buy |
| EOLS | Evolus | $14.71 | $16.00 | 8.77% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $19.46 | $18.67 | -4.06% | Buy |
OPTN Forecast FAQ
Is OptiNose a good buy?
Yes, according to 5 Wall Street analysts, OptiNose (OPTN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of OPTN's total ratings.
What is OPTN's price target?
OptiNose (OPTN) average price target is $4 with a range of $3 to $5, implying a 320.30% from its last price of $0.952. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will OptiNose stock go up soon?
According to Wall Street analysts' prediction for OPTN stock, the company can go up by 320.30% (from the last price of $0.952 to the average price target of $4), up by 425.38% based on the highest stock price target, and up by 215.23% based on the lowest stock price target.
Can OptiNose stock reach $1?
OPTN's average twelve months analyst stock price target of $4 supports the claim that OptiNose can reach $1 in the near future.
What are OptiNose's analysts' financial forecasts?
OptiNose's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $86.7M (high $92.86M, low $76.28M), average EBITDA is $-68.279M (high $-60.078M, low $-73.134M), average net income is $-39.724M (high $-33.107M, low $-44.166M), average SG&A $158.01M (high $169.24M, low $139.03M), and average EPS is $-0.264 (high $-0.22, low $-0.293). OPTN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $122.8M (high $131.29M, low $107.85M), average EBITDA is $-96.711M (high $-84.937M, low $-103M), average net income is $-10.549M (high $-8.505M, low $-11.871M), average SG&A $223.8M (high $239.27M, low $196.56M), and average EPS is $-0.07 (high $-0.0564, low $-0.0788).
Did the OPTN's actual financial results beat the analysts' financial forecasts?
Based on OptiNose's last annual report (Dec 2023), the company's revenue was $70.99M, beating the average analysts forecast of $65.15M by 8.95%. Apple's EBITDA was $-22.748M, missing the average prediction of $-51.312M by -55.67%. The company's net income was $-35.483M, missing the average estimation of $-64.06M by -44.61%. Apple's SG&A was $79.8M, missing the average forecast of $118.74M by -32.80%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.425 by -99.93%. In terms of the last quarterly report (Dec 2023), OptiNose's revenue was $19.86M, beating the average analysts' forecast of $19.26M by 3.12%. The company's EBITDA was $-4.948M, missing the average prediction of $-15.171M by -67.39%. OptiNose's net income was $-10.161M, missing the average estimation of $-12.388M by -17.98%. The company's SG&A was $18.96M, missing the average forecast of $35.11M by -45.99%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0822 by -99.88%